Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Microgynon · 1 trial · 1 indication
Plasma concentrations Ethinyl estradiol (EE) and levonorgestrel (LNG)
| Arm | Type | Description |
|---|---|---|
| Arm1 | EXPERIMENTAL | single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted) |
| Arm2 | EXPERIMENTAL | multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment, a single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted) |
| Name | Type | Description |
|---|---|---|
| Microgynon | DRUG | single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted) |
| Riociguat (Adempas,BAY63-2521) | DRUG | multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment |
Inclusion Criteria: * Healthy female subject * Non-smokers of at least 3 month before screening * Age: 52 to 65 years (inclusive) at the first screening examination * Ethnicity: white * Body mass index (BMI)\>=20 and \<=32 kg/m2 * Postmenopausal state, defined as * Medical history, if applicable (n...
Microgynon is a small molecule drug developed by Bayer AG. It has been studied in the context of drug interactions, specifically in a Phase 1 trial involving healthy postmenopausal women. The drug is not approved for the studied indication and remains investigational.
Microgynon was evaluated in a drug interaction study to assess its effects when co-administered with riociguat. The study was conducted in healthy postmenopausal women to investigate potential interactions. The results of this study are not detailed here.
Microgynon is developed by Bayer AG, a multinational pharmaceutical company. Bayer AG trades on the OTC market under the ticker BAYRY. The company is responsible for the clinical development of Microgynon.
Microgynon is in Phase 1 clinical development. A Phase 1 trial has been completed, but no active trials are currently listed. The drug has not been approved for any indication and remains investigational.
Microgynon has been studied in one completed clinical trial: NCT02159326, titled 'Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women.' This Phase 1 trial enrolled 31 participants in Germany and was completed.